Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6


SATB2 Protein Expression by Immunohistochemistry is a Sensitive and Specific Marker of Appendiceal and Rectosigmoid Well Differentiated Neuroendocrine Tumors.

Hoskoppal D, Epstein JI, Gown AM, Arnold Egloff SA, Gordetsky J, Shi CC, Giannico GA.

Histopathology. 2019 Oct 9. doi: 10.1111/his.14012. [Epub ahead of print]


Urinary Metabolomics Validates Metabolic Differentiation Between Renal Cell Carcinoma Stages and Reveals a Unique Metabolic Profile for Oncocytomas.

Falegan OS, Arnold Egloff SA, Zijlstra A, Hyndman ME, Vogel HJ.

Metabolites. 2019 Jul 24;9(8). pii: E155. doi: 10.3390/metabo9080155.


MAGI2 is an independent predictor of biochemical recurrence in prostate cancer.

David SN, Arnold Egloff SA, Goyal R, Clark PE, Phillips S, Gellert LL, Hameed O, Giannico GA.

Prostate. 2018 Jun;78(8):616-622. doi: 10.1002/pros.23506. Epub 2018 Mar 14.


Alternative splicing of ALCAM enables tunable regulation of cell-cell adhesion through differential proteolysis.

Hebron KE, Li EY, Arnold Egloff SA, von Lersner AK, Taylor C, Houkes J, Flaherty DK, Eskaros A, Stricker TP, Zijlstra A.

Sci Rep. 2018 Feb 16;8(1):3208. doi: 10.1038/s41598-018-21467-x.


Larger core size has superior technical and analytical accuracy in bladder tissue microarray.

Eskaros AR, Egloff SA, Boyd KL, Richardson JE, Hyndman ME, Zijlstra A.

Lab Invest. 2017 Mar;97(3):335-342. doi: 10.1038/labinvest.2016.151. Epub 2017 Jan 23.


Shed urinary ALCAM is an independent prognostic biomarker of three-year overall survival after cystectomy in patients with bladder cancer.

Arnold Egloff SA, Du L, Loomans HA, Starchenko A, Su PF, Ketova T, Knoll PB, Wang J, Haddad AQ, Fadare O, Cates JM, Lotan Y, Shyr Y, Clark PE, Zijlstra A.

Oncotarget. 2017 Jan 3;8(1):722-741. doi: 10.18632/oncotarget.13546.

Supplemental Content

Loading ...
Support Center